health economics and health care management

Font size »A . A+ . A++ .

RESEARCH GROUP "ECONOMIC EVALUATION":

Postal address:

Helmholtz Zentrum München
German Research Center for Environmental Health
Institute of Health Economics and Health Care Management (IGM)
P.O.Box 1129
D-85758 Neuherberg
Germany
Tel.: +49-89 / 3187-4176
Fax: +49-89 / 3187-3375
eMail:      

 


Renée Stark, M.D., MPH, FRCP(C)

Position:

Research Associate

 

Academic Record:

  • Medical Degree (M.D.), University of Alberta, Canada
  • FRCP(C), Internal Medicine, University of Calgary, Canada
  • Endocrinology and Metabolism Fellowship, Washington University, St. Louis, Missouri, USA
  • Master of Public Health (MPH) at the Ludwig-Maximilians-University Munich
    •  

 

Research Interests:

  • Economic aspects of adverse drug events
  • Measurement of costs and health related quality of life in chronic diseases (e.g. inflammatory bowel diseases, diabetes mellitus)
  • Prediction and extrapolation of medication costs
  • Analysis of cost data with generalised linear models

 

Current Research Projects:

  • Health economic evaluation of disease management programs for coronary heart disease
  • Health economic evaluation of disease management programs for Type 2 diabetes
  • Economic aspects of adverse drug events and their prevention by qualified advice by a pharmacist
  • Prevalence and costs of adverse drug events
  • Health economic evaluation of inflammatory bowel diseases

 

Publications:

  • Stark, R., John, J, Leidl, R.: Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: A scenario approach. BMC Health Services Research 11, 9 (2011)
  • Stark, R., Schunk, M., Meisinger, C., Rathmann, W., Leidl, R., Holle, R.: Medical care of type 2 diabetes in German disease management programs: a population-based evaluation. Diabetes Metab Res Rev 27(4), 383-391 (2011)
  • Findeisen, H.M., Weckbach, S., Stark, R.G., Reiser, M.F., Schoenberg, S.O., Parhofer, K.G.: Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus. Cardiovascular Diabetology 9, 44 (2010)
  • Stark, R., Reitmeir, P., Leidl, R., Konig HH.: Validity, Reliability, and Responsiveness of the EQ-5D in Inflammatory Bowel Disease in Germany. Inflammatory Bowel Disease 16, 42-51 (2010)
  • Parhofer, K.G., Zeymer, U., Stark, R.G., Binz, C., Schwertfeger, M., Bhatt, D. L., Steg, Ph. G., Röther, J.: In Germany Diabetic Patients with Coronary Artery Disease are Treated More Intensively than Diabetic Patients with Other Manifestations of Atherothrombosis – Results from the REACH Registry. Exp Clin Endocrinol Diabetes (epub ahead of print)
  • Stark, R., Schunk, M., Leidl, R., Meisinger, C., Holle, R.: [Process evaluation of Disease Management Programs for Type 2 Diabetes based on a representative population in the area of Augsburg (KORA)]. Betriebswirtschaftliche Forschung und Praxis 61 (3), 283-301 (2009)
  • Weckbach, S., Findeisen, H.M., Schoenberg, S.O., Kramer, H., Stark, R., Clevert, D.A., Reiser, M.F., Parhofer, K.G.: Systemic Cardiovascular Complications in Patients With Long-Standing Diabetes Mellitus: Comprehensive Assessment With Whole-Body Magnetic Resonance Imaging/Magnetic Resonance Angiography. Invest Radiol. 44, 242–250 (2009)
  • Broedl, U.C., Lebherz, C., Lehrke, M., Stark, R., Greif, M., Becker, A., von Ziegler, F., Tittus, J., Reiser, M., Becker, C., Göke, B., Parhofer, K., Leber, A.W.: Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques. PLoS ONE 4(3), (2009)
  • Lehrke, M., Konrad, A., Schachinger, V., Tillack, C., Seibold, F., Stark, R., Parhofer, K.G., Broedl, U.C.: CXCL16 is a surrogate marker of inflammatory bowel disease. Scand J Gastroenterol. 43, 283-288 (2008)
  • Konrad, A., Lehrke, M., Schachinger, V., Seibold, F., Stark, R., Ochsenkuhn, T., Parhofer, K.G., Goke, B., Broedl, U.C.: Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 19,1070-1074 (2007)
  • Broedl, U.C., Schachinger, V., Lingenhel, A., Lehrke, M., Stark, R., Seibold, F., Göke, B., Kronenberg, F., Parhofer, K.G., Konrad-Zerna, A.: Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. Inflamm Bowel Dis. 13, 391-397 (2007)
  • Stark, R., Konig, H.H., Leidl, R.: Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 24, 797-814 (2006)
  • von Kries, R., Ihme, N., Oberle, D., Lorani, A., Stark, R., Altenhofen, L., Niethard, F.U.: Effect of ultrasound screening on the rate of first operative procedures for developmental hip dysplasia in Germany. Lancet 362, 1883-1887 (2003)
  • Mühlberger, N., Behrend, C., Stark, R., Holle, R.: Datenbankgestützte Online-Erfassung von Arzneimitteln im Rahmen gesundheitswissenschaftlicher Studien – Erfahrungen mit der IDOM-Software. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 4, 601-611 (2003)
  • Ryan, E.A., Stark, R., Crockford, P.M., Suthijumroon, A.: Assessment of value of glycosylated albumin and protein in detection of gestational diabetes. Diabetes Care 10, 213-216 (1987)

 

 

back to Team